Ongoing clinical trials with FOXP3+ Tregs in the field of kidney transplantation could provide useful hindsight for the therapeutic application of FOXP3+ Tregs in primary glomerulopathies and systematic autoimmune diseases of native kidneys. Here, FOXP3 is linked to glomerular disorder.